CORNELISSEN, Jan J., Alois GRATWOHL, Richard F. SCHLENK, Gorge SIERRA, Martin BORNHÄUSER, Gunnar JULIUSSON, Zdeněk RÁČIL, Jacob M. ROWE, Nigel RUSSELL, Mohamad MOHTY, Bob LÖWENBERG, Gerard SOCIÉ, Dietger NIEDERWIESER and Gert J. GERT J. OSSENKOPPELE. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nature reviews. Clinical oncology. London: Macmillan Publishers Limited, 2012, vol. 9, No 10, p. 579-590. ISSN 1759-4774. doi:10.1038/nrclinonc.2012.150.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
Authors CORNELISSEN, Jan J. (528 Netherlands, guarantor), Alois GRATWOHL (756 Switzerland), Richard F. SCHLENK (276 Germany), Gorge SIERRA (724 Spain), Martin BORNHÄUSER (276 Germany), Gunnar JULIUSSON (752 Sweden), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Jacob M. ROWE (752 Sweden), Nigel RUSSELL (826 United Kingdom of Great Britain and Northern Ireland), Mohamad MOHTY (250 France), Bob LÖWENBERG (528 Netherlands), Gerard SOCIÉ (250 France), Dietger NIEDERWIESER (276 Germany) and Gert J. GERT J. OSSENKOPPELE (528 Netherlands).
Edition Nature reviews. Clinical oncology. London, Macmillan Publishers Limited, 2012, 1759-4774.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 15.031
RIV identification code RIV/00216224:14110/12:00060839
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1038/nrclinonc.2012.150
UT WoS 000309550800010
Keywords in English allogeneic haematopoietic stem-cell transplantation; AML
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 19. 2. 2013 23:28.
Abstract
Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality and morbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic- HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that allogeneic HSCT might be favoured if the projected disease-free survival is expected to improve by at least 10% based on an individual’s risk assessment. The approach requires initial disease risk assessment, identifying a sibling or unrelated donor soon after diagnosis and the incorporation of time-dependent risk factors, all within the context of an integrated therapeutic management approach.
PrintDisplayed: 12. 8. 2022 17:07